FinTrust Capital Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

FinTrust Capital Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13	Closed	-$1.43K	–	1377
2023 Q2	$1.43K	Hold	13	–	–	﹤0.01%	1065
2023 Q1	$1.43K	Hold	13	–	–	﹤0.01%	1058
2022 Q4	$1.43K	Sell	13 -84	-87%	-$5.45K	﹤0.01%	1055
2022 Q3	$5K	Buy	+97	New	+$4.44K	﹤0.01%	1029

FinTrust Capital Advisors's RXDX Position: Q3 2023 in Review

FinTrust Capital Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q3 2023, closing a stake of 13 shares — an estimated $1.43K sold.

FinTrust Capital Advisors first reported a position in RXDX in Q3 2022 and held it in 4 quarters. The position peaked at $5K in Q3 2022. 0 funds tracked by Wall St. Rank hold RXDX as of Q3 2023.

FinTrust Capital Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
FinTrust Capital Advisors sold 13 Prometheus Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $1.43K.
FinTrust Capital Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
FinTrust Capital Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $5K in Q3 2022.
0 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q3 2023.

Based on FinTrust Capital Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.